ConductScience.org, home

Paper10691586

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

Vadhan-Raj S and 10 others. Ann Intern Med, 2000. Cited by 140 papers, by iCite.

Cite this record

ConductScience Library. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Papers, record 10691586. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10691586

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
PubMed
Journal
Ann Intern Med
PubMed
Year
2000
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
140
iCite
Relative citation ratio, by iCite
3.32
iCite
Revised in PubMed
2022-03-21
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vadhan-Raj SS
2Verschraegen CFC F
3Bueso-Ramos CC
4Broxmeyer HEH E
5Kudelkà APA P
6Freedman RSR S
7Edwards CLC L
8Gershenson DD
9Jones DD
10Ashby MM
11Kavanagh JJJ J

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CarboplatinMajor topic
Genital Neoplasms, FemaleMajor topic
ThrombocytopeniaMajor topic
ThrombopoietinMajor topic
Analysis of Variance
Dose-Response Relationship, Drug
Female
Humans
Platelet Count
Platelet Transfusion
Recombinant Proteins

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 HL53586NHLBI NIH HHSUnited StatesP01HL053586PubMed and NIHNIH RePORTER
R01 HL54037NHLBI NIH HHSUnited StatesR01HL054037PubMed and NIHNIH RePORTER
R01 HL56416NHLBI NIH HHSUnited StatesR01HL056416PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.

PMIDTitleJournalYearIn PapersSource
42854051Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer: Insights and outcomes.Medicine (Baltimore)2026https://conductscience.org/library/papers/42854051PubMed
42658302Efficacy and clinical outcomes of proximal splenic artery embolization in patients with chemotherapy induced thrombocytopenia.Langenbecks Arch Surg2026https://conductscience.org/library/papers/42658302PubMed
42222375Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods.Front Oncol2026https://conductscience.org/library/papers/42222375PubMed
41932340Dietary restriction mitigates 5-fluorouracil-induced thrombocytopenia in aged mice via mitochondrial potentiation in hematopoietic stem cells and megakaryocyte progenitors.Stem Cell Reports2026https://conductscience.org/library/papers/41932340PubMed
41629833Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia.BMC Cancer2026https://conductscience.org/library/papers/41629833PubMed
41063990Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.Front Immunol2025https://conductscience.org/library/papers/41063990PubMed
40904833A nomogram for predicting the risk of chemoradiotherapy-associated thrombocytopenia in patients with esophageal cancer: a real-world cohort study.Ther Adv Med Oncol2025https://conductscience.org/library/papers/40904833PubMed
40003683Thrombocytopenia in Sepsis.Life (Basel)2025https://conductscience.org/library/papers/40003683PubMed
39495281Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia.Ann Hematol2024https://conductscience.org/library/papers/39495281PubMed
38077816Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors.Res Pract Thromb Haemost2023https://conductscience.org/library/papers/38077816PubMed
37749031[Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)].Zhonghua Xue Ye Xue Za Zhi2023https://conductscience.org/library/papers/37749031PubMed
37259024Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.BMC Cancer2023https://conductscience.org/library/papers/37259024PubMed
37039010Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.Expert Rev Hematol2023https://conductscience.org/library/papers/37039010PubMed
36865986Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.Ther Adv Hematol2023https://conductscience.org/library/papers/36865986PubMed
36695938Chemotherapy-induced thrombocytopenia: literature review.Discov Oncol2023https://conductscience.org/library/papers/36695938PubMed
36485134Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.Hematology Am Soc Hematol Educ Program2022https://conductscience.org/library/papers/36485134PubMed
36430539A Novel Antithrombocytopenia Agent, Rhizoma cibotii, Promotes Megakaryopoiesis and Thrombopoiesis through the PI3K/AKT, MEK/ERK, and JAK2/STAT3 Signaling Pathways.Int J Mol Sci2022https://conductscience.org/library/papers/36430539PubMed
35679540Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.PLoS One2022https://conductscience.org/library/papers/35679540PubMed
35642485Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.Haematologica2022https://conductscience.org/library/papers/35642485PubMed
35554955
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.
Hematol Oncol2022https://conductscience.org/library/papers/35554955PubMed

See all 51 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
THPO7066PubTator's text mininghttps://conductscience.org/library/genes/7066

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10691586

GET https://conductscience.org/api/papers/v1/10691586/cited_by?page=2